CNS peroxiredoxins and their regulation in health and disease

Antioxidants and Redox Signaling

Volumn 14, Issue 8, 2011, Pages 1467-1477

  Bell, Karen F S ^a   Hardingham, Giles E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PEROXIDE; PEROXIREDOXIN; PEROXIREDOXIN 2; THIOL; THIOREDOXIN; THIOREDOXIN REDUCTASE; TRANSCRIPTION FACTOR NRF2;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DOWN SYNDROME; ENZYME ACTIVE SITE; ENZYME REGULATION; HUMAN; NEUROPROTECTION; NONHUMAN; OXIDATION; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; STROKE; SYNAPSE; UPREGULATION;

ANIMALS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; HEALTH; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXIREDOXINS;

EID: 79952831852     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2010.3567     Document Type: Article

References (104)

1. Adams SM, de Rivero Vaccari JC, and Corriveau RA. Pronounced cell death in the absence of NMDA receptors in the developing somatosensory thalamus. J Neurosci 24: 9441-9450, 2004. (Pubitemid 39426180)
2. Al-Mubarak B, Soriano FX, and Hardingham GE. Synaptic NMDAR activity suppresses FOXO1 expression via a cisacting FOXO binding site: FOXO1 is a FOXO target gene. Channels (Austin) 3: DOI: 10.4161=chan 3.4.9381 2009 3.4.9381, 2009.
3. Allen CL and Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 4: 461-470, 2009.
4. Aoyama K, WatabeM, and Nakaki T. Regulation of neuronal glutathione synthesis. J Pharmacol Sci 108: 227-238, 2008.
5. Aran M, Ferrero DS, Pagano E, and Wolosiuk RA. Typical 2-Cys peroxiredoxins. Modulation by covalent transformations and noncovalent interactions. FEBS J 276: 2478-2493, 2009.
6. Biteau B, Labarre J, and Toledano MB. ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin. Nature 425: 980-984, 2003. (Pubitemid 37376931)
7. Boulos S, Meloni BP, Arthur PG, Bojarski C, and Knuckey NW. Peroxiredoxin 2 overexpression protects cortical neuronal cultures from ischemic and oxidative injury but not glutamate excitotoxicity, whereas Cu=Zn superoxide dismutase 1 overexpression protects only against oxidative injury. J Neurosci Res 85: 3089-3097, 2007. (Pubitemid 350057364)
8. Brouns R and De Deyn PP. The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg 111: 483-495, 2009.
9. Budanov AV, Sablina AA, Feinstein E, Koonin EV, and Chumakov PM. Regeneration of peroxiredoxins by p53- regulated sestrins, homologs of bacterial AhpD. Science 304: 596-600, 2004. (Pubitemid 38541920)
10. Camacho A and Massieu L. Role of glutamate transporters in the clearance and release of glutamate during ischemia and its relation to neuronal death. Arch Med Res 37: 11-18, 2006. (Pubitemid 41727885)
11. Chang TS, Jeong W, Woo HA, Lee SM, Park S, and Rhee SG. Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J Biol Chem 279: 50994-51001, 2004. (Pubitemid 40017840)
12. Chen H, Song YS, and Chan PH. Inhibition of NADPH oxidase is neuroprotective after ischemia-reperfusion. J Cereb Blood Flow Metab 29: 1262-1272, 2009.
13. Chen W, Ji J, Xu X, He S, and Ru B. Proteomic comparison between human young and old brains by two-dimensional gel electrophoresis and identification of proteins. Int J Dev Neurosci 21: 209-216, 2003. (Pubitemid 36636973)
14. Cho HY, Jedlicka AE, Reddy SP, Kensler TW, Yamamoto M, Zhang LY, and Kleeberger SR. Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 26: 175-182, 2002. (Pubitemid 34107870)
15. Choi DW. Calcium-mediated neurotoxicity: Relationship to specific channel types and role in ischemic damage. Trends Neurosci 11: 465-469, 1988.
16. Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson VL, and Dawson TM. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304: 1328-1331, 2004. (Pubitemid 38697430)
17. Cumming RC, Dargusch R, Fischer WH, and Schubert D. Increase in expression levels and resistance to sulfhydryl oxidation of peroxiredoxin isoforms in amyloid betaresistant nerve cells. J Biol Chem 282: 30523-30534, 2007. (Pubitemid 350035173)
18. Das KC and Das CK. Thioredoxin, a singlet oxygen quencher and hydroxyl radical scavenger: Redox independent functions. Biochem Biophys Res Commun 277: 443-447, 2000.
19. Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T, Harada T, and Yamamoto M. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 59: 169-177, 2001. (Pubitemid 32117993)
20. Essler S, Dehne N, and Brune B. Role of sestrin2 in peroxide signaling in macrophages. FEBS Lett 583: 3531-3535, 2009.
21. Fang J, Nakamura T, Cho DH, Gu Z, and Lipton SA. Snitrosylation of peroxiredoxin 2 promotes oxidative stressinduced neuronal cell death in Parkinson's disease. Proc Natl Acad Sci USA 104: 18742-18747, 2007. (Pubitemid 350210767)
22. Forder JP and Tymianski M. Postsynaptic mechanisms of excitotoxicity: Involvement of postsynaptic density proteins, radicals, and oxidant molecules. Neuroscience 158: 293-300, 2009.
23. Giudice A and Montella M. Activation of the Nrf2-ARE signaling pathway: A promising strategy in cancer prevention. Bioessays 28: 169-181, 2006.
24. Gould E, Cameron HA, and McEwen BS. Blockade of NMDA receptors increases cell death and birth in the developing rat dentate gyrus. J Compar Neurol 340: 551-565, 1994. (Pubitemid 24045565)
25. Halliwell B. Oxidative stress and neurodegeneration: Where are we now? J Neurochem 97: 1634-1658, 2006. (Pubitemid 43873658)
26. Hardingham GE. Pro-survival signalling from the NMDA receptor. Biochem Soc Trans 34: 936-938, 2006. (Pubitemid 44796454)
27. Hardingham GE. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans 37: 1147-1160, 2009.
28. Hardingham GE, Fukunaga Y, and Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5: 405-414, 2002. (Pubitemid 34454245)
29. Harman D. Aging: A theory based on free radical and radiation chemistry. J Gerontol 11: 298-300, 1956.
30. Hattori F, Murayama N, Noshita T, and Oikawa S. Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo. J Neurochem 86: 860-868, 2003. (Pubitemid 36988798)
31. Hetman M and Kharebava G. Survival signaling pathways activated by NMDA receptors. Curr Top Med Chem 6: 787-799, 2006.
32. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, and Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem 274: 27891-27897, 1999.
33. Hwang IK, Yoo KY, Kim DW, Lee CH, Choi JH, Kwon YG, Kim YM, Choi SY, and Won MH. Changes in the expression of mitochondrial peroxiredoxin and thioredoxin in neurons and glia and their protective effects in experimental cerebral ischemic damage. Free Radic Biol Med 48: 1242-1251, 2010.
34. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, and Olney JW. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283: 70-74, 1999. (Pubitemid 29044848)
35. Ikonomidou C, Stefovska V, and Turski L. Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc Natl Acad Sci USA 97: 12885-12890, 2000.
36. Jakel RJ, Townsend JA, Kraft AD, and Johnson JA. Nrf2- mediated protection against 6-hydroxydopamine. Brain Res 1144: 192-201, 2007. (Pubitemid 46440842)
37. Jin MH, Lee YH, Kim JM, Sun HN, Moon EY, Shong MH, Kim SU, Lee SH, Lee TH, Yu DY, and Lee DS. Characterization of neural cell types expressing peroxiredoxins in mouse brain. Neurosci Lett 381: 252-257, 2005. (Pubitemid 40719167)
38. Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, and Chen PC. The Nrf2-ARE pathway: An indicator and modulator of oxidative stress in neurodegeneration. Ann NY Acad Sci 1147: 61-69, 2008.
39. Kensler TW, Wakabayashi N, and Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2- ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116, 2007.
40. Kim SH, Fountoulakis M, Cairns N, and Lubec G. Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl 61: 223-235, 2001. (Pubitemid 38085085)
41. Kim SU, Jin MH, Kim YS, Lee SH, Cho YS, Cho KJ, Lee KS, Kim YI, Kim GW, Kim JM, Lee TH, Lee YH, Shong M, Kim HC, Chang KT, Yu DY, and Lee DS. Peroxiredoxin II preserves cognitive function against age-linked hippocampal oxidative damage. Neurobiol Aging 2009. DOI: 10.1016= j.neurobiolaging 2009.05.
42. Kim YC, Masutani H, Yamaguchi Y, Itoh K, Yamamoto M, and Yodoi J. Hemin-induced activation of the thioredoxin gene by Nrf2. A differential regulation of the antioxidant responsive element by a switch of its binding factors. J Biol Chem 276: 18399-18406, 2001.
43. Kraft AD, Johnson DA, and Johnson JA. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 24: 1101-1112, 2004. (Pubitemid 38177017)
44. Krapfenbauer K, Engidawork E, Cairns N, Fountoulakis M, and Lubec G. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res 967: 152-160, 2003. (Pubitemid 36324297)
45. Lau D and Bading H. Synaptic activity-mediated suppression of p53 and induction of nuclear calcium-regulated neuroprotective genes promote survival through inhibition of mitochondrial permeability transition. J Neurosci 29: 4420-4429, 2009.
46. Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ, Jakel RJ, and Johnson JA. Nrf2, a multi-organ protector? FASEB J 19: 1061-1066, 2005.
47. Lee JM, Shih AY, Murphy TH, and Johnson JA. NFE2- related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 278: 37948-37956, 2003. (Pubitemid 37175325)
48. Lee KS, Iijima-Ando K, Iijima K, Lee WJ, Lee JH, Yu K, and Lee DS. JNK=FOXO-mediated neuronal expression of fly homologue of peroxiredoxin II reduces oxidative stress and extends life span. J Biol Chem 284: 29454-29461, 2009.
49. Leveille F, Papadia S, Fricker M, Bell KF, Soriano FX, Martel MA, Puddifoot C, Habel M, Wyllie DJ, Ikonomidou C, Tolkovsky AM, and Hardingham GE. Suppression of the intrinsic apoptosis pathway by synaptic activity. J Neurosci 30: 2623-2635, 2010.
50. Leveille F, Soriano FX, Papadia S, and Hardingham GE. Excitotoxic insults lead to peroxiredoxin hyperoxidation. Oxid Med Cell Longev 2: 110-113, 2009.
51. Lipton SA. NMDA receptor activity regulates transcription of antioxidant pathways. Nat Neurosci 11: 381-382, 2008. (Pubitemid 351441871)
52. Lipton SA, Nakamura T, Yao D, Shi ZQ, Uehara T, and Gu Z. Comment on "S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function". Science 308: 1870; author reply 1870, 2005.
53. Liu H, Nishitoh H, Ichijo H, and Kyriakis JM. Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol Cell Biol 20: 2198-2208, 2000. (Pubitemid 30123835)
54. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, and Yankner BA. Gene regulation and DNA damage in the ageing human brain. Nature 429: 883-891, 2004. (Pubitemid 38843301)
55. Mariani E, Polidori MC, Cherubini A, and Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview. J Chromatogr B Analyt Technol Biomed Life Sci 827: 65-75, 2005. (Pubitemid 41551598)
56. Martel M, Wyllie DJ, and Hardingham GE. In developing hippocampal neurons, NR2B-containing NMDA receptors can mediate signalling to neuronal survival and synaptic potentiation, as well as neuronal death. Neuroscience 158: 334-343, 2009.
57. Monti B and Contestabile A. Blockade of the NMDA receptor increases developmental apoptotic elimination of granule neurons and activates caspases in the rat cerebellum. Eur J Neurosci 12: 3117-3123., 2000.
58. Musicco C, Capelli V, Pesce V, Timperio AM, Calvani M, Mosconi L, Zolla L, Cantatore P, and Gadaleta MN. Accumulation of overoxidized peroxiredoxin III in aged rat liver mitochondria. Biochim Biophys Acta 1787: 890-896, 2009.
59. Nadeau PJ, Charette SJ, Toledano MB, and Landry J. Disulfide bond-mediated multimerization of Ask1 and its reduction by thioredoxin-1 regulate H(2)O(2)-induced c-Jun NH(2)-terminal kinase activation and apoptosis. Mol Biol Cell 18: 3903-3913, 2007. (Pubitemid 47519483)
60. Nakamura T and Lipton SA. Cell death: Protein misfolding and neurodegenerative diseases. Apoptosis 14: 455-468, 2009.
61. Nguyen T, Yang CS, and Pickett CB. The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med 37: 433-441, 2004. (Pubitemid 38901076)
62. Ogusucu R, Rettori D, Munhoz DC, Netto LE, and Augusto O. Reactions of yeast thioredoxin peroxidases I and II with hydrogen peroxide and peroxynitrite: Rate constants by competitive kinetics. Free Radic Biol Med 42: 326-334, 2007. (Pubitemid 46038040)
63. Papadia S, Soriano FX, Leveille F, Martel MA, Dakin KA, Hansen HH, Kaindl A, Sifringer M, Fowler J, Stefovska V, McKenzie G, Craigon M, Corriveau R, Ghazal P, Horsburgh K, Yankner BA, Wyllie DJ, Ikonomidou C, and Hardingham GE. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 11: 476-487, 2008. (Pubitemid 351441886)
64. Papadia S, Stevenson P, Hardingham NR, Bading H, and Hardingham GE. Nuclear Ca2\+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection. J Neurosci 25: 4279-4287, 2005. (Pubitemid 40628772)
65. Patenaude A, Murthy MR, and Mirault ME. Emerging roles of thioredoxin cycle enzymes in the central nervous system. Cell Mol Life Sci 62: 1063-1080, 2005. (Pubitemid 40868526)
66. Peskin AV, Low FM, Paton LN, Maghzal GJ, Hampton MB, and Winterbourn CC. The high reactivity peroxiredoxin 2 with H2O2 is not reflected in its reaction with other oxidants and thiol reagents. J Biol Chem 282: 11885-11892, 2007. (Pubitemid 47100684)
67. Pohl D, Ishmaru MJ, Bittigau P, Stadhaus D, Hubner C, Olney JW, Turski L, and Ikonomidou C. NMDA antagonists and apoptotic cell death triggered by head trauma in developing rat brain. Proc Natl Acad Sci USA 96: 2508-2513, 1999. (Pubitemid 29117946)
68. Qu D, Rashidian J, Mount MP, Aleyasin H, Parsanejad M, Lira A, Haque E, Zhang Y, Callaghan S, Daigle M, Rousseaux MW, Slack RS, Albert PR, Vincent I, Woulfe JM, and Park DS. Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron 55: 37-52, 2007. (Pubitemid 46990825)
69. Radyuk SN, Michalak K, Klichko VI, Benes J, Rebrin I, Sohal RS, and Orr WC. Peroxiredoxin 5 confers protection against oxidative stress and apoptosis and also promotes longevity in Drosophila. Biochem J 419: 437-445, 2009.
70. Rashidian J, Rousseaux MW, Venderova K, Qu D, Callaghan SM, Phillips M, Bland RJ, During MJ, Mao Z, Slack RS, and Park DS. Essential role of cytoplasmic cdk5 and Prx2 in multiple ischemic injury models, in vivo. J Neurosci 29: 12497-12505, 2009.
71. Reed TT, Pierce WM, Jr., Turner DM, Markesbery WR, and Butterfield DA. Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J Cell Mol Med 13: 2019-2029, 2009.
72. Rhee SG, Jeong W, Chang TS, and Woo HA. Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. Kidney Int Suppl 106: S3-8, 2007. (Pubitemid 47172555)
73. Rhee SG, Woo HA, Bae SH, and Park S. Sestrin 2 is not a reductase for cysteine sulfinic acid of peroxiredoxins. Antioxid Redox Signal 11: 739-745, 2009.
74. Rossi DJ, Oshima T, and Attwell D. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature 403: 316-321, 2000. (Pubitemid 30062388)
75. Salih DA and Brunet A. FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr Opin Cell Biol 20: 126-136, 2008.
76. Sarafian TA, Verity MA, Vinters HV, Shih CC, Shi L, Ji XD, Dong L, and Shau H. Differential expression of peroxiredoxin subtypes in human brain cell types. J Neurosci Res 56: 206-212, 1999. (Pubitemid 29201059)
77. Satoh T, Okamoto SI, Cui J, Watanabe Y, Furuta K, Suzuki M, Tohyama K, and Lipton SA. Activation of the Keap1=Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers. Proc Natl Acad Sci USA 103: 768-773, 2006. (Pubitemid 43153100)
78. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, and Lee RT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 279: 30369-30374, 2004. (Pubitemid 38937964)
79. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, and Murphy TH. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 23: 3394-3406, 2003. (Pubitemid 36531981)
80. Shih AY, Li P, and Murphy TH. A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J Neurosci 25: 10321-10335, 2005. (Pubitemid 41636229)
81. Smith PD, Crocker SJ, Jackson-Lewis V, Jordan-Sciutto KL, Hayley S, Mount MP, O'Hare MJ, Callaghan S, Slack RS, Przedborski S, Anisman H, and Park DS. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 100: 13650-13655, 2003. (Pubitemid 37444794)
82. Soriano FX, Baxter P, Murray LM, Sporn MB, Gillingwater TH, and Hardingham GE. Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin. Mol Cells 27: 279-282, 2009.
83. Soriano FX and Hardingham GE. Compartmentalized NMDA receptor signalling to survival and death. J Physiol 584: 381-387, 2007. (Pubitemid 47578325)
84. Soriano FX, Leveille F, Papadia S, Higgins LG, Varley J, Baxter P, Hayes JD, and Hardingham GE. Induction of sulfiredoxin expression and reduction of peroxiredoxin hyperoxidation by the neuroprotective Nrf2 activator 3H- 1,2-dithiole-3-thione. J Neurochem 107: 533-543, 2008.
85. Stocker R. Antioxidant activities of bile pigments. Antioxid Redox Signal 6: 841-849, 2004. (Pubitemid 39237937)
86. Suh SW, Shin BS, Ma H, Van Hoecke M, Brennan AM, Yenari MA, and Swanson RA. Glucose and NADPH oxidase drive neuronal superoxide formation in stroke. Ann Neurol 64: 654-663, 2008.
87. Sun KH, de Pablo Y, Vincent F, and Shah K. Deregulated Cdk5 promotes oxidative stress and mitochondrial dysfunction. J Neurochem 107: 265-278, 2008.
88. Sykiotis GP and Bohmann D. Keap1=Nrf2 signaling regulates oxidative stress tolerance and lifespan in Drosophila. Dev Cell 14: 76-85, 2008.
89. Takagi Y, Hattori I, Nozaki K, Mitsui A, Ishikawa M, Hashimoto N, and Yodoi J. Excitotoxic hippocampal injury is attenuated in thioredoxin transgenic mice. J Cereb Blood Flow Metab 20: 829-833, 2000. (Pubitemid 30317057)
90. Takagi Y, Mitsui A, Nishiyama A, Nozaki K, Sono H, Gon Y, Hashimoto N, and Yodoi J. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc Natl Acad Sci USA 96: 4131-4136, 1999. (Pubitemid 29169048)
91. Tashiro A, Sandler VM, Toni N, Zhao C, and Gage FH. NMDA-receptor- mediated, cell-specific integration of new neurons in adult dentate gyrus. Nature 442: 929-933, 2006. (Pubitemid 44285949)
92. Thomas CG, Miller AJ, and Westbrook GL. Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. J Neurophysiol 95: 1727-1734, 2006.
93. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, Masliah E, Nomura Y, and Lipton SA. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 441: 513-517, 2006. (Pubitemid 44050153)
94. Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J, and Nikaido T. Thioredoxin- dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274: 35809-35815, 1999. (Pubitemid 129512885)
95. Wang Q, Zhao X, He S, Liu Y, An M, and Ji J. Differential proteomics analysis of specific carbonylated proteins in the temporal cortex of aged rats: The deterioration of antioxidant system. Neurochem Res 35: 13-21, 2010.
96. Wood ZA, Schroder E, Robin Harris J, and Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28: 32-40, 2003. (Pubitemid 36051004)
97. Yan W, Wang HD, Hu ZG, Wang QF, and Yin HX. Activation of Nrf2-ARE pathway in brain after traumatic brain injury. Neurosci Lett 431: 150-154, 2008.
98. Yang L, Calingasan NY, Thomas B, Chaturvedi RK, Kiaei M, Wille EJ, Liby KT, Williams C, Royce D, Risingsong R, Musiek ES, Morrow JD, Sporn M, and Beal MF. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One 4: e5757, 2009.
99. Yao J, Taylor M, Davey F, Ren Y, Aiton J, Coote P, Fang F, Chen JX, Yan SD, and Gunn-Moore FJ. Interaction of amyloid binding alcohol dehydrogenase=Abeta mediates upregulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model. Mol Cell Neurosci 35: 377-382, 2007. (Pubitemid 46843572)
100. Yoo KY, Park OK, Yu J, Yan B, Li H, Lee CH, Choi JH, Kim DW, Hwang IK, and Won MH. Expression and changes of hyperoxidized peroxiredoxins in non-pyramidal and polymorphic cells in the gerbil hippocampus during normal aging. Cell Mol Neurobiol 29: 413-421, 2009.
101. Yoshida T, Nakamura H, Masutani H, and Yodoi J. The involvement of thioredoxin and thioredoxin binding protein- 2 on cellular proliferation and aging process. Ann NY Acad Sci 1055: 1-12, 2005. (Pubitemid 43211660)
102. Yoshida Y, Yoshikawa A, Kinumi T, Ogawa Y, Saito Y, Ohara K, Yamamoto H, Imai Y, and Niki E. Hydroxyoctadecadienoic acid and oxidatively modified peroxiredoxins in the blood of Alzheimer's disease patients and their potential as biomarkers. Neurobiol Aging 30: 174-185, 2009.
103. Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 38: 769-789, 2006. (Pubitemid 44903268)
104. Zhang SJ, Zou M, Lu L, Lau D, Ditzel DA, Delucinge- Vivier C, Aso Y, Descombes P, and Bading H. Nuclear calcium signaling controls expression of a large gene pool: identification of a gene program for acquired neuroprotection induced by synaptic activity. PLoS Genet 5: e1000604, 2009.